The advantage of this nanocarrier was that by functionalizing with angiopep-2, a specific ligand of low density lipoprotein receptor-related protein-1, which could mediate the system to penetrate the blood–brain barrier and target glioma cells, DOX was specifically delivered to glioma cells and expanded the median survival time of glioma-bearing mice. Here, LRP1 is linked to central nervous system cancer.